Cybin (NYSE American: CYBN) (NEO: CYBN) is a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options. The company today announced that the first participants have been dosed with CYB004 in its ongoing three-part phase 1 clinical trial evaluating intravenous N,N-dimethyltryptamine (“IV DMT”) and CYB004 in healthy … Continue reading InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Initiates Dosing of First Participants in Phase 1 Clinical Trial